[HTML][HTML] Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience

S Chartrand, JJ Swigris, L Stanchev, JS Lee… - Respiratory …, 2016 - Elsevier
Objective To describe the clinical phenotype and natural history of a cohort of patients with
interstitial pneumonia with autoimmune features (IPAF). Methods A retrospective, single …

[HTML][HTML] Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

…, V Morin, E Rich, JR Goulet, S Chartrand… - Arthritis Research & …, 2020 - Springer
Objective To describe successful therapeutic strategies in statin-induced anti-HMGCR
myopathy. Methods Retrospective data from a cohort of 55 patients with statin-induced anti-…

[HTML][HTML] Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials

…, A Fischer, P Richette, S Chartrand… - JCR: Journal of …, 2021 - journals.lww.com
Background/Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of
rheumatoid arthritis (RA). Interstitial lung disease (ILD) is an extra-articular manifestation of RA. …

[PDF][PDF] Rituximab for the treatment of connective tissue disease-associated interstitial lung disease

S Chartrand, JJ Swigris, L Peykova… - Sarcoidosis Vasc Diffuse …, 2016 - researchgate.net
Objective: To describe our experience with rituximab (RTX) as treatment for a diverse
spectrum of chronic connective tissue disease-associated interstitial lung disease (CTD-ILD). …

A multidisciplinary evaluation helps identify the antisynthetase syndrome in patients presenting as idiopathic interstitial pneumonia

S Chartrand, JJ Swigris, L Peykova, J Chung… - The journal of …, 2016 - jrheum.org
Introduction. Interstitial lung disease (ILD) is 1 possible manifestation of the idiopathic
inflammatory myopathies (IIM). Occasionally, patients presenting with ILD are mistakenly …

Clinical characteristics and natural history of autoimmune forms of interstitial lung disease: a single-center experience

S Chartrand, JS Lee, JJ Swigris, L Stanchev, A Fischer - Lung, 2019 - Springer
Objective To describe the phenotypic characteristics and natural history of patients with
autoimmune forms of interstitial lung disease (ILD). Methods Retrospective, descriptive, single-…

Current approach to connective tissue disease-associated interstitial lung disease

JJ Solomon, S Chartrand, A Fischer - Current Opinion in …, 2014 - journals.lww.com
… a ; Chartrand, Sandra a,b ; Fischer, Aryeh a … Sandra Chartrand received bursary
funding from Fondation de l’Hôpital Maisonneuve-Rosemont and Bourse de …

[PDF][PDF] Assessment and management of connective tissue disease associated interstitial lung disease

S Chartrand, A Fischer - Sarcoidosis Vasc Diffuse Lung Dis, 2015 - researchgate.net
The intersection of the connective tissue diseases (CTD) and the interstitial lung diseases (ILD)
is complex. Although often considered as a single entity,“CTD-ILD” actually reflects a …

Management of Connective Tissue Disease–associated Interstitial Lung Disease

S Chartrand, A Fischer - Rheumatic Disease Clinics, 2015 - rheumatic.theclinics.com
Although connective tissue disease (CTD)–associated interstitial lung diseases (ILDs) are
sometimes considered a homogeneous entity (such as in this and many other articles), the …

[PDF][PDF] The initial stage of canine endotoxin shock as an expression of anaphylactic shock: studies on complement titers and plasma histamine concentrations

…, RB Davis, R Potter, S Chartrand - The Journal of Clinical …, 1964 - Am Soc Clin Investig
Methods Animals. A total of 85 adult mongrel dogs was used in a series of 10 experiments.
Endotoxin. The same lot of E. coli endotoxin was used throughout and was prepared as …